Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
NCT06824818
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Elderly
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 70 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- University of Chicago
- Last updated on ClinicalTrials.gov
- October 1, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- The University of Illinois at Chicago (UIC) · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.